Endoscopic bariatric treatments improve fibrosis in NAFLD

Patients with non-alcoholic fatty liver disease who underwent endoscopic bariatric and metabolic therapies saw improvements in liver fibrosis and other outcomes, according to study results.Christopher C. Thompson, MD, MSc, from the division of gastroenterology, hepatology and endoscopy at Brigham and Women’s Hospital, and colleagues wrote that even as relative new treatments, endoscopic bariatric and metabolic therapies (EBMT) have already shown benefits in terms of weight loss.“Studies have demonstrated their efficacy to range from 10% to 20% total weight loss with the majorityRead More

Share on facebook
Share on twitter
Share on linkedin